Literature DB >> 6998251

Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man.

B S Hansen, M Dam, J Brandt, E F Hvidberg, H Angelo, J M Christensen, P Lous.   

Abstract

Interactions between analgesics and anti-epileptic drugs may sometimes present a serious clinical problem. The aim of the study was to investigate the influence of usually applied doses of dextropropoxyphene (DPX) on the steady state levels of carbamazepine (CBZ), phenytoin (DPH) and phenobarbital (PB). Sixteen patients in monotherapy completed the trial, while four patients dropped out. In patients on CBZ serum levels increased (mean appr. 66%) after 6 days on DPX. In three of the patients a further increase was seen after an additional week on DPX. One patient discontinued the DPX intake because of clinical signs of toxicity, but the remainder were clinically unaffected. CBZ-epoxide levels declined simultaneously. For DPH only a doubtful increase was observed after 1-2 weeks on DPX. For PB an average increase of 20% in serum level was noted after 1 week. The protein binding of CBZ and DPH was not affected. It is concluded that patients on CBZ should be treated only with DPX if monitored properly. Patients on DPH or PB should be followed carefully until further evidence has been produced.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6998251     DOI: 10.1111/j.1600-0404.1980.tb01505.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  12 in total

Review 1.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 2.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 3.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 4.  Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nolan; Anthony G Marson; Jennifer Weston; Catrin Tudur Smith
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

Review 5.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

6.  Interaction between carbamazepine and dextropropoxyphene.

Authors:  Y L Yu; C Y Huang; D Chin; E Woo; C M Chang
Journal:  Postgrad Med J       Date:  1986-03       Impact factor: 2.401

Review 7.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

8.  Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition.

Authors:  R A Robson; J O Miners; A G Whitehead; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

9.  [Sustained-release dextropropoxyphene.].

Authors:  K Kurz-Müller; M Zenz
Journal:  Schmerz       Date:  1991-12       Impact factor: 1.107

10.  Interaction of propoxyphene with diazepam, alprazolam and lorazepam.

Authors:  D R Abernethy; D J Greenblatt; D S Morse; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.